Ticagrelor Tablet
Product Images NDC 72516-018

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72516-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oryza Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A cumulative percentage line graph comparing Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose. The vertical axis represents cumulative percentage, and Ticagrelor shows a higher cumulative percentage than Clopidogrel throughout the time period. The graph includes patient numbers at risk at various time points and a summary box with event and KM percentages at 12 months for both drugs.*
FDA Label Image

Fiigure_2 (Figure 2)

Fiigure_2 (Figure 2)
A vertical bar chart showing the percentage of patients who had an event following CABG over multiple days. The X-axis represents days 1 through 8 or more, and the Y-axis shows the percentage from 0 to 100. Two data series labeled 'T' and 'C' are compared for each day, with values provided below the chart. The chart visually compares event rates post-CABG between these two groups over time.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of ticagrelor, showing its molecular framework with a fluorinated phenyl group, a thiazole ring, and a substituted ribose sugar moiety.*
FDA Label Image

Figure_8 (Figure 08)

Figure_8 (Figure 08)
A forest plot chart showing the mean effect and 90% confidence interval for drug interactions with Ticagrelor. The chart compares changes in pharmacokinetic parameters Cmax and AUC relative to reference values for various interacting drugs, with recommendations on dose adjustments or use. The x-axis represents change relative to reference, with Cmax and AUC indicated by square and triangle markers, respectively.*
FDA Label Image

Figure_10 (Figure 10)

Figure_10 (Figure 10)
A cumulative percentage survival curve chart showing clinical event rates over 360 days comparing Ticagrelor 90 mg versus Clopidogrel. The x-axis is days from randomization, and the y-axis is cumulative percentage. The chart includes patient event counts, hazard ratio with confidence interval, and p-value, illustrating comparative outcomes.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
A forest plot chart illustrating the overall treatment effect of Ticagrelor versus Clopidogrel across various patient characteristics and subgroups. The horizontal axis displays hazard ratios (HR) with 95% confidence intervals, comparing efficacy outcomes between the two drugs in categories such as geographic region, ASA dose, treatment approach, PCI timing, diabetes history, age group, sex, and race.*
FDA Label Image

Figure_12 (Figure 12)

Figure_12 (Figure 12)
A forest plot presenting hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor and Clopidogrel effectiveness across different aspirin dose ranges and geographic regions (US and Non-US). The plot shows effect estimates with dots and confidence intervals, indicating whether Ticagrelor or Clopidogrel is favored.*
FDA Label Image

Figure_13 (Figure 13)

Figure_13 (Figure 13)
A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo over approximately 1300 days from randomization. The graph shows cumulative percentage on the Y-axis and days from randomization on the X-axis. A risk table is included below the graph showing numbers at risk at various time points for each group.*
FDA Label Image

Figure_14 (Figure 14)

Figure_14 (Figure 14)
A forest plot chart illustrating the overall treatment effect of Ticagrelor 90 mg compared to placebo across various subgroups including age, sex, race, weight, BMI, geographic region, medical history, and other clinical factors. The horizontal axis represents hazard ratios indicating Ticagrelor or placebo benefit, with confidence intervals for each subgroup.*
FDA Label Image

Figure_15 (Figure 15)

Figure_15 (Figure 15)
A line graph showing cumulative percentage (%) over months from randomization for Ticagrelor and placebo groups. The solid line represents Ticagrelor with events recorded as 736 out of 9619, and the dashed line represents placebo with events recorded as 818 out of 9601. A table below the x-axis shows the number of subjects at risk over time for both groups.*
FDA Label Image

Figure_16 (Figure 16)

Figure_16 (Figure 16)
A forest plot chart showing hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor and placebo across various patient characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, and medical history factors. The plot visually presents the relative effectiveness or outcomes between Ticagrelor and placebo groups in these subpopulations.*
FDA Label Image

Figure_17 (Figure 17)

Figure_17 (Figure 17)
A Kaplan-Meier curve comparing cumulative event percentages over 34 days from randomization between Ticagrelor 90 mg twice daily (solid line) and placebo (dashed line). The chart shows fewer cumulative events in the Ticagrelor group compared to placebo, with event counts and percentages noted. The x-axis represents days from randomization, and the y-axis shows cumulative percentage of events.*
FDA Label Image

Figure_18 (Figure 18)

Figure_18 (Figure 18)
A forest plot chart depicting hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo across various patient characteristics such as age, sex, race, weight, BMI, geographic region, and medical history. The graph visually represents treatment effect size, favoring ticagrelor or placebo along the x-axis from 0.5 to 2.0.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
A cumulative percentage line graph showing events over 54 months from randomization for Ticagrelor and Placebo groups. The graph plots the cumulative percentage on the y-axis against months on the x-axis, with Ticagrelor represented by a solid line and Placebo by a dashed line. A table below the x-axis shows the number of subjects at risk over time for each group.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily (solid line) versus placebo (dashed line) over approximately 30 days from randomization. The vertical axis represents cumulative percentage incidence. The chart includes event counts and sample sizes for each group, with Ticagrelor showing a higher cumulative percentage than placebo across the period. The bottom of the chart displays the number of subjects at risk over time for both groups.*
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
Line graph depicting IPA (%) induced by 20 µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. Ticagrelor shows the highest IPA percentage increasing rapidly and maintaining near 90% from 2 to 8 hours, Clopidogrel shows moderate increase reaching around 50%, and placebo remains near baseline throughout.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
A line graph comparing IPA (%) induced by 20μM ADP over time for Ticagrelor, Clopidogrel, and Placebo. Time is shown in days on the main x-axis, and a smaller inset graph shows time in hours. Ticagrelor and Clopidogrel show higher IPA percentages initially that decrease over time, while Placebo remains low throughout.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
A chart labeled 'Mean effect and 90% CI' comparing Ticagrelor to AR-C124910XX across intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The chart shows mean effects and 90% confidence intervals with markers for Cmax and AUC, alongside recommendations indicating no dose adjustment is required for each factor. Footnotes explain single-dose and study limitations in hepatic impairment.*
FDA Label Image

Figure_9 (Image 09)

Figure_9 (Image 09)
A chart illustrating the mean effect and 90% confidence interval of ticagrelor doses on the pharmacokinetics (Cmax and AUC) of various interacting drugs including simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine. The chart compares change relative to the interacting drug alone and includes dose adjustment recommendations.*
FDA Label Image

90 mg 60 Count Label (Image 90)

90 mg 60 Count Label (Image 90)
Ticagrelor 90 mg oral tablets packaging label from Oryza Pharmaceuticals, Inc., containing 60 tablets. The label includes dosage information, storage instructions, distributor and manufacturer details, a barcode, and the NDC number 72516-018.*
FDA Label Image

Logo (Logo0001 01)

Logo (Logo0001 01)
FDA Label Image

Logo0001-02 (Logo0001 02)

Logo0001-02 (Logo0001 02)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.